Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
11 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07065344 | A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region(DOMAIN) | recruiting | — | 500 | AstraZenecaINDUSTRY | 10 | Sep 23, 2026 | clinicaltrials |
| NCT05894239 | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer(INAVO122) | recruiting | Phase 3 | 230 | Hoffmann-La Roche |
| 29 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT07806266 | EORTC Metastatic Breast Cancer Module Development | recruiting | — | 568 | University of LeedsOTHER | 14 | Sep 8, 2026 | clinicaltrials |
| NCT07801235 | HYperfractionated Radiation Therapy Versus Concurrent Chemoradiation for Head and Neck Cancer (HYTC) | recruiting | N/A | 604 | King Hussein Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07371403 | MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia | recruiting | N/A | 12 | King Hussein Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05592938 | Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)(PRESERVE) | recruiting | N/A | 171 | University Health Network, TorontoOTHER | 10 | Jul 17, 2026 | clinicaltrials |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC(KANGUROO) | recruiting | Phase 2 / Phase 3 | 71 | Urovant Sciences GmbHINDUSTRY | 16 | Jun 15, 2026 | clinicaltrials |
| NCT05430971 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry | recruiting | — | 200 | Immune Oncology Research InstituteOTHER | 15 | Jun 5, 2026 | clinicaltrials |
| NCT06528691 | Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors | recruiting | Phase 2 | 52 | St. Jude Children's Research HospitalOTHER | 4 | May 13, 2026 | clinicaltrials |
| NCT07271121 | Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL | recruiting | Phase 2 | 26 | King Hussein Cancer CenterOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT05190094 | Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.(ICRG0201) | recruiting | Phase 2 | 80 | International Cancer Research Group, United Arab EmiratesOTHER | 3 | May 7, 2025 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials